Contrasting VBI Vaccines (NASDAQ:VBIV) & Xilio Therapeutics (NASDAQ:XLO)

VBI Vaccines (NASDAQ:VBIVGet Free Report) and Xilio Therapeutics (NASDAQ:XLOGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.


This table compares VBI Vaccines and Xilio Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -881.79% -525.42% -45.87%
Xilio Therapeutics N/A -153.48% -89.26%

Analyst Recommendations

This is a breakdown of current recommendations for VBI Vaccines and Xilio Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 0 0 N/A
Xilio Therapeutics 0 0 1 0 3.00

Valuation & Earnings

This table compares VBI Vaccines and Xilio Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $8.68 million 1.97 -$92.84 million N/A N/A
Xilio Therapeutics N/A N/A -$76.40 million ($2.57) -0.37

Xilio Therapeutics has lower revenue, but higher earnings than VBI Vaccines.

Risk & Volatility

VBI Vaccines has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Insider and Institutional Ownership

12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Xilio Therapeutics beats VBI Vaccines on 5 of the 9 factors compared between the two stocks.

About VBI Vaccines

(Get Free Report)

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

About Xilio Therapeutics

(Get Free Report)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with's FREE daily email newsletter.